Over the past several weeks, China has consistently made headlines with large pharmaceuticals and biotechs making their way into the country. For example, Sanofi-aventis recently acquired BMP Sunstone and established a consumer health JV with Minsheng Pharmaceutical (see the November 2, 2010 LRTJ), ...
This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!
News Commentary | April 16, 2021
The CEO of Pear Therapeutics is claiming that trial irregularities are causing misleading results regarding the schizophrenia product rolled out last year. While the results of this study are unlikely to change anything for Pear Therapeutics directly, the claimed lack of rigor in the trial speaks to... Not part of subscription
News Commentary | May 24, 2021
This will further expand Hummingbird's proprietary Rational Antibody Discovery (RAD) platform for novel therapeutic monoclonal antibodies. The market for therapeutic antibodies is rapidly growing, as new drugs have been approved for treating various human diseases, including many cancers and ... Not part of subscription
News Commentary | July 19, 2021
Biogen's AD drug, Aduhelm, continues to stir controversy, as several private insurers have decided not to cover the high costs of the medication. This includes some affiliates of Blue Cross Blue Shield and even the CMS, despite the FDA's accelerated approval. With pharmaceuticals like Roche and Eli ... Not part of subscription